Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Proc Natl Acad Sci U S A
1994 Jul 19;9115:7046-50.
Show Gene links
Show Anatomy links
Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors.
Schambye HT
,
Hjorth SA
,
Bergsma DJ
,
Sathe G
,
Schwartz TW
.
???displayArticle.abstract???
To characterize binding sites for nonpeptide angiotensin antagonists on the human angiotensin II receptor type 1 (AT1 receptor) we have systematically exchanged segments of the human receptor with corresponding segments from a homologous Xenopus laevis receptor, which does not bind the nonpeptide compounds. Substitution of transmembrane segment VII of the human AT1 receptor dramatically reduced the binding affinity of all of the 11 nonpeptide antagonists tested (55- to > 2000-fold) with no effect on the binding of angiotensin. The affinity for the nonpeptide compounds decreased additionally one order of magnitude when transmembrane segment VI and the connecting extracellular loop 3 from the Xenopus receptor were also introduced into the human AT1 receptor. Exchanges of smaller segments and single residues in transmembrane segments VI and VII and extracellular loop 3 revealed that the binding of nonpeptide antagonists was dependent on nonconserved residues located deep within the transmembrane segments VI and VII, in particular Asn295 in transmembrane segment VII. Surprisingly, all exchanges in transmembrane segment VII, including the Asn295 to Ser substitution, had a more pronounced effect on the binding of the competitive antagonists relative to the insurmountable antagonists. It is concluded that the binding mode for peptide and nonpeptide ligands on the AT1 receptor is rather different and that competitive and insurmountable antagonists presumably bind to overlapping but distinct sites located in transmembrane segments VI and VII.
Beinborn,
A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists.
1993, Pubmed
Beinborn,
A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists.
1993,
Pubmed
Bergsma,
Cloning and characterization of a human angiotensin II type 1 receptor.
1992,
Pubmed
,
Xenbase
Bergsma,
Isolation and expression of a novel angiotensin II receptor from Xenopus laevis heart.
1993,
Pubmed
,
Xenbase
Bradbury,
New nonpeptide angiotensin II receptor antagonists. 2. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy)quinoline derivatives.
1992,
Pubmed
Carini,
Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives.
1991,
Pubmed
Chang,
In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist.
1992,
Pubmed
Chang,
Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands.
1990,
Pubmed
Chiu,
Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent.
1990,
Pubmed
Fong,
Localization of agonist and antagonist binding domains of the human neurokinin-1 receptor.
1992,
Pubmed
,
Xenbase
Fong,
Amino-aromatic interaction between histidine 197 of the neurokinin-1 receptor and CP 96345.
1993,
Pubmed
Gether,
Different binding epitopes on the NK1 receptor for substance P and non-peptide antagonist.
1993,
Pubmed
Gether,
Chimeric NK1 (substance P)/NK3 (neurokinin B) receptors. Identification of domains determining the binding specificity of tachykinin agonists.
1993,
Pubmed
Gether,
Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors.
1993,
Pubmed
Horton,
Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension.
1989,
Pubmed
James,
Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues.
1991,
Pubmed
Ji,
Novel angiotensin II antagonists distinguish amphibian from mammalian angiotensin II receptors expressed in Xenopus laevis oocytes.
1991,
Pubmed
,
Xenbase
Ji,
Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan.
1994,
Pubmed
Johansen,
Biosynthesis of peptide precursors and protease inhibitors using new constitutive and inducible eukaryotic expression vectors.
1990,
Pubmed
Ogletree,
Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist.
1993,
Pubmed
Olins,
In vitro pharmacology of a nonpeptidic angiotensin II receptor antagonist, SC-51316.
1992,
Pubmed
Sheikh,
Binding of monoiodinated neuropeptide Y to hippocampal membranes and human neuroblastoma cell lines.
1989,
Pubmed
Weinstock,
1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists.
1991,
Pubmed
Wienen,
Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies.
1992,
Pubmed
Wienen,
Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277.
1993,
Pubmed
Wong,
Nonpeptide angiotensin II receptor antagonists. I. Pharmacological characterization of 2-n-butyl-4-chloro-1-(2-chlorobenzyl)imidazole-5-acetic acid, sodium salt (S-8307).
1988,
Pubmed
Zhang,
Characterization of BIBS 39 and BIBS 222: two new nonpeptide angiotensin II receptor antagonists.
1992,
Pubmed
Zoffmann,
Conserved HisVI-17 of the NK-1 receptor is involved in binding of non-peptide antagonists but not substance P.
1993,
Pubmed